Health
AstraZeneca details clinical trial failure of experimental heart disease drug
A Phase 3 study showed no added benefit from an experimental silencer drug when patients were already taking stabilizer medication.
The short version
- AstraZeneca and Ionis Pharmaceuticals reported that their Phase 3 trial for an experimental ATTR-CM silencer drug failed to show additional benefits for patients already on a stabilizer drug.
- Most trial participants were already taking a stabilizer medication at the beginning of the study.
- The results affect rival companies in the multi-billion dollar ATTR-CM market, including Alnylam Pharmaceuticals and BridgeBio.
- Industry analysts suggested the outcome strengthens the case that oral stabilizers may be more effective than injectable silencers.
Key facts
- AstraZeneca provided details on the failure of a Phase 3 trial testing an experimental silencer drug developed with Ionis Pharmaceuticals for ATTR-CM.[STAT]
- The trial demonstrated no additional health improvements for ATTR-CM patients who were already receiving a stabilizer drug.[STAT]
- A majority of trial participants were taking a stabilizer drug at the start of the study.[STAT]
- The findings carry commercial implications for competitors in the ATTR-CM treatment market, such as Alnylam Pharmaceuticals and BridgeBio.[STAT]
What remains uncertain
- The full long-term commercial impact on injectable silencer drugs versus oral stabilizers remains subject to ongoing market assessment.[STAT]